Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: An interventional cohort study

BMC Nephrology

Thomas Marwick³  David W Mudge³  Nicole M Isbel²  Scott B Campbell²  David W Johnson³  Janine K Jeffries²  Aya Matsumoto⁴  Jeffrey Coombes⁴  Carmel M Hawley²  Brian Haluska¹  Leanne Jeffriess¹  Carolyn L van Eps³ 

[1] Department of Cardiology, Princess Alexandra Hospital, Ipswich Rd, Brisbane, 4102, Australia;Department of Nephrology Princess Alexandra Hospital, Ipswich Rd, Brisbane, 4102, Australia;School of Medicine, University of Queensland, Ipswich Rd, Brisbane, 4102 Australia;Department of Human Movements, University of Queensland, St Lucia, Brisbane, 4067, Australia

关键词: Arterial Compliance;    Oxidative Stress;    Carotid Intima-Media Thickness;    Nocturnal Hemodialysis;    Left Ventricular Hypertrophy;    Left Ventricular Mass Index;    Ejection Fraction;    Diastolic Function;   

Others  :  1083232
DOI  :  10.1186/1471-2369-12-51

 received in 2011-03-23, accepted in 2011-10-03,  发布年份 2011

【 摘 要 】

Background

Nightly extended hours hemodialysis may improve left ventricular hypertrophy and function and endothelial function but presents problems of sustainability and increased cost. The effect of alternate nightly home hemodialysis (NHD) on cardiovascular structure and function is not known.

Methods

Sixty-three patients on standard hemodialysis (SHD: 3.5-6 hours/session, 3-5 sessions weekly) converted to NHD (6-10 hours/session overnight for 3-5 sessions weekly). 2Dimensional transthoracic echocardiography and ultrasound measures of brachial artery reactivity (BAR), carotid intima-media thickness (CIMT), total arterial compliance (TAC) and augmentation index (AIX) were performed post dialysis at baseline and 18-24 months following conversion to NHD. In 37 patients, indices of oxidative stress: plasma malonyldialdehyde (MDA) and anti-oxidant enzymes: catalase (CAT), glutathione peroxidase (GPX) and superoxide dismutase (SOD) activity and total antioxidant status (TAS) were measured at baseline, 3 and 6 months.

Results

Left ventricular mass index (LVMI) remained stable. Despite significant derangement at baseline, there were no changes in diastolic function measures, CIMT, BAR and TAC. AIX increased. Conversion to NHD improved bone mineral metabolism parameters and blood pressure control. Interdialytic weight gains increased. No definite improvements in measures of oxidative stress were demonstrated.

Conclusions

Despite improvement in uremic toxin levels and some cardiovascular risk factors, conversion to an alternate nightly NHD regimen did not improve cardiovascular structure and function. Continuing suboptimal control of uremic toxins and interdialytic weight gains may be a possible explanation. This study adds to the increasing uncertainty about the nature of improvement in cardiovascular parameters with conversion to intensive hemodialysis regimens. Future randomized controlled trials will be important to determine whether increases in dialysis session duration, frequency or both are most beneficial for improving cardiovascular disease whilst minimizing costs and the impact of dialysis on quality of life.

【 授权许可】

   
2011 van Eps et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Australia and New Zealand Dialysis and Transplant Registry Annual Reports [http://www.anzdata.org.au/v1/annual_reports_download.html] webcite
• [2]Foley R, Parfrey P, Harnett J, Kent G, Martin C, Murray D, Barre P: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995, 47(1):186-192.
• [3]Josephs W, Odenthal H, Lenga P, Wiechmann H: Doppler echocardiography description of diastolic function disorders in terminal renal failure. In New characterization of uremic cardiomyopathy Edited by Cardiol Z. 1990, 79:482-8.
• [4]London G: Cardiovascular disease in chronic renal failure: Pathophysiologic aspects. Semin Dial 2003, 16:2. 85-94
• [5]Hampl H, Riedel E: Cardiac disease in the dialysis patient: Good, better, best clinical practice: Blood Purif. 2009, 27:99-113.
• [6]London G, Marchais S, Guerin A, Metivier F, Adda H: Arterial stiffness and function in end-stage renal disease. Nephrol Dial Transplant 2002, 17:1713-1724.
• [7]London G, Marchais S, Guerin A: Arterial stiffness and function in End-stage renal disease. Adv Chronic Kidney Dis 2004, 11(2):202-209.
• [8]Longencker J, Coresh J, Powe N, Levey A, Fink N, Martin A, Klag M: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 2002, 13:1918-1927.
• [9]Zoccali C, Tripepi G, Mallamaci F: Predictors of cardiovascular death in ESRD. Semin Nephrol 2005, 25(6):358-362.
• [10]Munter P, He J, Astor B, Folsom A, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005, 16:529-538.
• [11]Zoccali C, Mallamaci F, Tripepi G: Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004, 15:S77-S80.
• [12]Pierratos A: Daily nocturnal home hemodialysis. Kidney Int 2004, 65:1975-1986.
• [13]Pierratos A, McFarlane P, Chan C: Quotidian dialysis-update 2005. Current Opinions in Nephrology and Hypertension 2005, 14:119-124.
• [14]Chan C: Cardiovascular effects of home intensive hemodialysis. Adv Chronic Kidney Dis 2009, 16(3):173-178.
• [15]Walsh M, Culleton B, Tonelli M, Manns B: A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism and health-related quality of life. Kidney Int 2005, 67:1500-1508.
• [16]Blagg C, Lindsay R, Eds: The London daily/nocturnal hemodialysis study. Am J Kidney Dis 2003., 42(Supp 1)
• [17]Ayus J, Mizani M, Achinger S, Thadhani R, Go A, Lee S: Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005, 16(9):2778-88.
• [18]Fagugli R, Reboldi G, Quintaliani G, Pasini P, Ciao G, Cicconi B, Pasticci F, Kaufman J, Buoncristiani U: Short daily haemodialysis: blood pressure control and left ventricular mass reduction in hypertensive haemodialysis patients. Am J Kidney Dis 2001, 28(2):371-376.
• [19]Culleton B, Malsh M, Klarenbach S, Mortis G, Scott-Douglas N, Quinn R, Tonelli M, Donnelly S, Friedrich M, Kumar A, Mahallati H, Hemmelgarn B, Manns B: Effect of frequent nocturnal haemodialysis vs conventional haemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 2007, 298(11):1291-1299.
• [20]Chan C, Harvey P, Picton P, et al.: Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003, 42:925-931.
• [21]Chan C, Mardirossian S, Faratro R, et al.: Improvement in lower extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis 2003, 41:225-229.
• [22]Chan C, Jain V, Picton P, et al.: Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int 2005, 68:338-344.
• [23]Schiller N, Shah P, Crawford l, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, schnittger I: Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiography 1989, 2:358-67.
• [24]Zoccali C, Benedetto F, Mallamaci F, Tripepi G, Giacone G, Caraliotti A, Seminara G, Stancanelli B, Malatino L: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001, 12:2768-2774.
• [25]DuBois D, DuBois EF: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Medicine 1916, 17:863-71.
• [26]Ommen S, Nishimura R: A clinical approach to the assessment of left ventricular diastolic function by Doppler echocardiography: update 2003. Heart 2003, 89(Suppl III):18-23.
• [27]Sorensen K, Celermajer D, Speigelhalter D, Georgakopoulos D, Robinson J, Thomas O, Deanfield J: Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995, 74:247-253.
• [28]Fathi R, Marwick T: Noninvasive tests of vascular function and structure: Why and how to perform them. Am Heart J 2001, 141(5):694-703.
• [29]Bots M, Westerlink J, Rabelink T, Koning E: Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on FMD response. European Heart Journal 2004, 26(4):363-368.
• [30]Neutenteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, Bauer P, Weidinger F: Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997, 1111-1118.
• [31]Preston E, Ellis M, Kulinskaya E, Davies A, Brown E: Associations between carotid artery intima-media thickness and cardiovascular risk factors in CKD. Am J Kidney Dis 2005, 46(5):856-862.
• [32]Nishizawa Y, Shoji T, Mekawa K, et al.: Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2003, 41(Suppl 1):S76-S79.
• [33]Ishimura E, Taniwaki H, Tabata T, Tsujimoto Y, Jono S, Emoto M, Shojo T, Inaba M, Inoue T, Nishizawa Y: Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. Am J Kidney Dis 2005, 45(5):859-865.
• [34]Aminbakhsh A, Mancini G: Carotid intima-media thickness measurements: what defines abnormality? A systematic review, Clin Invest Med 1999, 22(4):149-57.
• [35]Fathi R, Haluska B, Isbel N, Short L, Marwick T: The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 2004, 43(4):616-23.
• [36]Stergiopulos N, Segers P, Westerhof N: Use of pulse pressure method for estimating total arterial compliance in vivo. Am J Physiol 1999, 276:H424-H428.
• [37]Stergiopulos N, Meister JJ, Westerhof N: Evaluation of methods for estimation of total arterial compliance. Am J Physiol 1995, 268:H1540-H1548.
• [38]Quinones M, Otto C, Stoddard M, Woggoner A, Zoghbi : Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler quantification task force of the nomenclature and standards committee of the American Society of Echocardiography, Journal of the American Society of Echocardiography 2002, 15(2):167-84.
• [39]Chen CH, Nevo E, Fetics B, et al.: Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function, Circulation 1997, 95:1827-36.
• [40]Stergiopulos N, Meister JJ, Westerhof N: Simple and accurate way for estimating total and segmental arterial compliance: the pulse pressure method. Ann Biomed Eng 1994, 22:392-7.
• [41]Mottram P, Haluska B, Leano R, Carlier S, Case C, Marwick T: Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart 2005, 91:1551-1556.
• [42]Haluska B, Jeffries L, Carlier S, Marwick T: Measurement of arterial distensibility and compliance to assess prognosis. Atherosclerosis 2010, 209:471-480.
• [43]Chen C, Nevo E, Fetics B, Pak P, Yin F, Maughan W, Kass : Estimation of central aortic pressure waveform by mathematical transformation of radial tanometry pressure: validation of generalized transfer function. Circulation 1997, 95:1827-1836.
• [44]Murgo J, Westerhoff N, Giolma J, Altobelli S: Aortic input impedance in normal man: relationship to pressure wave forms. Circulation 1980, 62:105-116.
• [45]Chung J, Lee Y, Kim J, Seong M, Kim S, Lee J, Ryu J, Choi J, Lim K, Chang S, Lee G, Kim S: Reference values for the augmentation index and pulse pressure in apparently healthy Korean subjects. Korean Circ J 2010, 40:165-171.
• [46]The FHN Trial Group: In-centre hemodialysis six times per week versus three times per week. The New England Journal of Medicine 2010, 363(24):2287-2300.
• [47]The FHN Trial Group: Effect of Nocturnal Home Hmeodialysis. Results presented in the Late Breaking clinical Trials session at American society of nephrology Meeting 2010.
• [48]Patel R, Mark P, Johnston N, McGregor E, Dargie H, Jardine A: Renal transplantation is not associated with regression of left ventricular hypertrophy: A magnetic resonance study. CJASN 2008, 3:1807-1811.
• [49]Dudziak M, Debska-Slizien , Rutkowski B: Cardiovascular effects of successful renal transplantation: A 30 month study on left ventricular morphology, systolic and diastolic functions. Transplant Proc 2005, 37(2):1039-1043.
• [50]Alpert M: Cardiac performance and morphology in end-stage renal disease. Am J Med Sci 2003, 325(4):168-178.
• [51]Chan C, Li S, Verma S: Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol 2005, 289:F679-F684.
• [52]Kocak H, Ceken K, Yavuz A, Yukel S, Gurkan A, Erdogan O, Ersoy F, Yakupoglu G, Demirbas A, Tuneer M: Effect of renal transplantation on endothelial function in haemodialysis patients. Nephrology Dialysis and Transplantation 2006, 21:203-207.
• [53]Yilmaz M, Saglam M, Carrero J, Qureshi A, Caglar K, Eyileten T, Sonmez A, Oguz Y, Aslan I, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J: Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009, 23(2):241-8.
• [54]Yilmaz M, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, Eyileten T, Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural A: Endothelial function improves with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005, 80(12):1660-6.
• [55]Caglar K, Yilmaz M, Saglam M, Cakir E, Kilic S, Eyileten T, Sonmez A, Oguz Y, Oner K, Ors F, Vural A, Yenicesu M: Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 2007, 83(4):392-7.
• [56]Passauer J, Bussemaker E, Lassig G, Gross P: Kidney Transplantation improves endothelium-dependent vasodilation in patients with end-stage renal disease. Transplantation 2003, 1907-1910.
• [57]De Lima J, Vieira M, Viviani L, Medeiros C, Ianhez L, Kopel L, de Andreda J, Krieger E, Lage S: Long-term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end stage renal failure patients. Nephrol Dial Transplant 2002, 17(4):645-51.
• [58]Litwin M, Jourdan C, Niemirska A, Schenk J, Jobs K, Grenda R, Wawer Z, Rajszys P, Mehls O, Schaefer F: Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrol Dial Transplant 2008, 23(8):2552-7.
• [59]Zoungas S, Kerr P, Chadban S, Muske C, Ristevski S, Atkins R, McNeill J, McGrath : Arterial function after successful renal transplantation. Kidney Int 2004, 65(5):1882-9.
• [60]Nishioka T, Akiyama T, Nose K, Koike H: Arterial stiffness after successful renal transplantation. Transplant Proc 2008, 40(7):2405-8.
• [61]Nafar M, Khatami F, Kardavani B, Farjad R, Pour-Reza_Gholi F, Firoozan A: Atherosclerosis after kidney transplantation: changes of intima-media thickness of carotids during early post transplant period. Urol J 2007, 4(2):105-10.
• [62]Covic A, Goldsmityh D, Gusbeth-Totomir P, Buhaescu I, Covic M: Successful renal transplantation decreases aortic stiffness and increases vascular reactivity in dialysis patients. Transplantation 2003, 76(11):1573-7.
• [63]Westhoffg T, Straub-Hohenbleicher H, Basdorf M, van der Giet S, Offerman G, Schlattmann P, Zidek W, van der Giet M: Time dependent effects of cadaveric renal transplantation on arterial compliance in patients with end stage kidney disease. Transplantation 2006, 81(10):1410-4.
• [64]Weinreich T, De los Rios T, Passlick-Deetjen J: Effects of an increase in time vs frequency on cardiovascular parameters in chronic haemodialysis patients. Clin Nephrol 2006, 66(6):433-9.
• [65]Covic A, Gusbeth-Tatomir P, Goldsmith D: Arterial stiffness in renal patients: An update. Am J Kidney Diseases 2005, 45(6):965-977.
• [66]Yilmaz M, Qureshi A, Carrero J, Saglam M, Suliman M, Caglar K, Eyileten T, Sonmez A, Oguz Y, Vural A, Yenicesu M, Axelsson J: Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant without overt cardiovascular disease. Am J Nephrol 2010, 31(3):214-21.
• [67]Singh A, Szczech L, Tang K, Barnhart H, et al.: Correction of anemia with erythropoietin alp[ha in chronic kidney disease. N Eng J Med 2006, 355(20):2085-2099.
• [68]Pfeffer M, Burdmann E, Chen C, Cooper M, de Zeeuw D, Eckardt K, Feyzi J, Ivanovich P, Kewalramani R, Levy A, et al.: A trial of darbepoietin alpha in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361(21):2019-32.
• [69]Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G, Ritz E: Atorvastatin in Patients with type 2 diabetes mellitus undergoing hemodialysis. N Eng J Med 2005, 353:238-48.
• [70]Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J, Chae D, Chevaile A, Cobbe S, et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Eng J Med 2009, 360(14):1395-407.
• [71]Isbel N, Haluska B, Johnson D, Beller E, Hawley C, Marwick T: Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 2006, 151:745-53.
• [72]Locatilli F, Canaud B, Eckardt K, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
• [73]Wratten M, Galaris D, Tetta C, Sevanian A: Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease. Antiox Redox Signal 2002, 4:935-944.
• [74]Crowther N, Polkinghorne K, Linehan L, Corradini A, Kerr P: Water soluble vitamin levels in home haemodialysis patients. Nephrology 2009., 14(Suppl 1) A6 Abstract Nr 20
• [75]Starling M, Crawford M, Sorensen S, Levi B, Richards K, O'Rourke R: Comparative accuracy of apical biplane cross-sectional echocardiography and gated equilibrium radionuclide angiography for estimating left ventricular size and performance. Circulation 1981, 63:1075-1084.